Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.36 |
| ▸ | HPGD | P15428 | 4/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | RAB9A | P51151 | 2/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13267665 | 0.90 | LMNA (0.39) | LMNAALDH1A1HPGDKDM4ETDP1 | |
| SCHEMBL10044834 | 0.87 | LMNA (0.38) | LMNAALDH1A1HPGDKDM4ETDP1 | |
| SCHEMBL708587 | 0.85 | ALDH1A1 (0.42) | LMNAALDH1A1HPGDKDM4EUSP2 | |
| SCHEMBL9188694 | 0.84 | LMNA (0.40) | LMNAALDH1A1HPGDKDM4EUSP2 | |
| SCHEMBL9196383 | 0.83 | LMNA (0.38) | LMNAALDH1A1HPGDUSP2SMN1; SMN2 | |
| SCHEMBL14435475 | 0.83 | ALDH1A1 (0.36) | LMNAALDH1A1HPGDKDM4ETDP1 | |
| SCHEMBL709956 | 0.81 | LMNA (0.33) | LMNAALDH1A1HPGD | |
| SCHEMBL9352729 | 0.81 | LMNA (0.59) | LMNAALDH1A1HPGDUSP2SMN1; SMN2 | |
| SCHEMBL9451103 | 0.81 | LMNA (0.59) | LMNAALDH1A1HPGDUSP2SMN1; SMN2 | |
| SCHEMBL710486 | 0.81 | LMNA (0.36) | LMNAALDH1A1HPGDUSP2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8124806-B2 | Contrast agents | GE HEALTHCARE AS (NO) | 2012-02-28 | — | — | US | disclosed |
| US-8124806-B2 | Contrast agents | GE HEALTHCARE AS (NO) | 2012-02-28 | — | — | US | disclosed |
| US-8124806-B2 | Contrast agents | GE HEALTHCARE AS (NO) | 2012-02-28 | — | — | US | disclosed |
| EP-1989179-B1 | CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2011-01-26 | — | — | EP | disclosed |
| EP-1989179-B1 | CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2011-01-26 | — | — | EP | disclosed |
| US-20100183522-A1 | CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2010-07-22 | — | — | US | disclosed |
| US-20100111875-A1 | TRISUBSTITUTED TRIAZAMACROCYCLIC COMPOUNDS AND THEIR USE AS CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2010-05-06 | — | — | US | disclosed |
| US-20100111875-A1 | TRISUBSTITUTED TRIAZAMACROCYCLIC COMPOUNDS AND THEIR USE AS CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2010-05-06 | — | — | US | disclosed |
| US-20090053142-A1 | CONTRAST AGENTS | WYNN DUNCAN | 2009-02-26 | — | — | US | disclosed |
| US-20090053142-A1 | CONTRAST AGENTS | WYNN DUNCAN | 2009-02-26 | — | — | US | disclosed |
| WO-2009005365-A1 | CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2009-01-08 | — | — | WO | disclosed |
| US-20080260651-A1 | CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2008-10-23 | — | — | US | disclosed |
| US-20080260651-A1 | CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2008-10-23 | — | — | US | disclosed |
| WO-2008123779-A1 | TRISUBSTITUTED TRIAZAMACROCYCLI C COMPOUNDS AND THEIR USE AS CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2008-10-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090053142-A1 | CONTRAST AGENTS | IPO4, TPO, IPO11 | LMNA 2151/4885ALDH1A1 3352/4885HPGD 3025/4885 |
| US-20080260651-A1 | CONTRAST AGENTS | IPO4, TPO, IPO11 | LMNA 2138/4885ALDH1A1 3375/4885HPGD 1100/4885 |
| US-20100183522-A1 | CONTRAST AGENTS | IPO4, IPO11, IPO8 | LMNA 2689/4885ALDH1A1 3910/4885HPGD 3657/4885 |
| US-20100111875-A1 | TRISUBSTITUTED TRIAZAMACROCYCLIC COMPOUNDS AND THEIR USE AS CONTRAST AGENTS | TBCA, THOC2, TCOF1 | LMNA 1434/4885ALDH1A1 3570/4885HPGD 1841/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.